Filing Flows › Core Laboratories (CLB) › Q2 2026 › vs Q2 2025
Core Laboratories (CLB) Q2 2026 vs Q2 2025 (year over year)
Core Laboratories's revenue fell $5.5M (-4%) from $130M in Q2 2025 to $125M in Q2 2026. The biggest changes: Product −$3.6M (-11%); Service −$1.9M (-2%). Operating margin 7.3% against 11.7% (-4.4 pts).
Core Laboratories, Q2 2026: revenue $125M (-4% year over year), operating margin 7.3%, net earnings $6.0M, operating cash flow $7.8M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 7.3% | 11.7% | -4.4 pts |
| Net margin | 4.8% | 8.2% | -3.4 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Service | $94.3M | $96.2M | −$1.9M | -2% |
| Product | $30.3M | $33.9M | −$3.6M | -11% |
| Revenue | $125M | $130M | −$5.5M | -4% |
| Operating profit | $9.2M | $15.3M | −$6.1M | -40% |
| Costs & expenses | $115M | $115M | $590K | +0.5% |
| Pre-tax earnings | $6.3M | $12.6M | −$6.3M | -50% |
| Other expense, net | $2.8M | $2.7M | $135K | +5% |
| Cost of revenue | $101M | $104M | −$2.3M | -2% |
| General & admin | $11.0M | $10.5M | $489K | +5% |
| Other operating costs | $3.1M | $703K | $2.4M | +346% |
| Loss borne by minority interests | $158K | −$33K | $191K | — |
| Net earnings | $6.0M | $10.6M | −$4.7M | -44% |
| Income tax | $507K | $1.9M | −$1.4M | -73% |
| Depreciation & amortization | $3.8M | $3.7M | $155K | +4% |
| Share-based compensation | $902K | $538K | $364K | +68% |
| Working capital & other | $2.9M | $921K | $2.0M | +212% |
| Operating cash flow | $7.8M | $13.9M | −$6.1M | -44% |
Questions
How much did Core Laboratories's revenue grow year over year in Q2 2026?
Core Laboratories's revenue fell $5.5M (-4%) from $130M in Q2 2025 to $125M in Q2 2026.
What drove Core Laboratories's revenue change in Q2 2026?
Product −$3.6M (-11%); Service −$1.9M (-2%).